|
1
|
Kumagai S, Kurumatani N, Arimoto A and
Ichihara G: Cholangiocarcinoma among offset colour proof-printing
workers exposed to 1,2-dichloropropane and/or dichloromethane.
Occup Environ Med. 70:508–510. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Faris JE and Zhu AX: Targeted therapy for
biliary tract cancers. J Hepatobiliary Pancreat Sci. 19:326–336.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sato J, Kimura T, Saito T, et al: Gene
expression analysis for predicting gemcitabine resistance in human
cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 18:700–711. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ohtaka K, Kohya N, Sato K, Kitajima Y, Ide
T, Mitsuno M and Miyazaki K: Ribonucleotide reductase subunit M1 is
a possible chemoresistance marker to gemcitabine in biliary tract
carcinoma. Oncol Rep. 20:279–286. 2008.PubMed/NCBI
|
|
5
|
Borbath I, Verbrugghe L, Lai R, Gigot JF,
Humblet Y, Piessevaux H and Sempoux C: Human equilibrative
nucleoside transporter 1 (hENT1) expression is a potential
predictive tool for response to gemcitabine in patients with
advanced cholangiocarcinoma. Eur J Cancer. 48:990–996. 2012.
View Article : Google Scholar
|
|
6
|
Meng F, Henson R, Lang M, et al:
Involvement of human micro-RNA in growth and response to
chemotherapy in human cholangiocarcinoma cell lines.
Gastroenterology. 130:2113–2129. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pignochino Y, Sarotto I, Peraldo-Neia C,
et al: Targeting EGFR/HER2 pathways enhances the antiproliferative
effect of gemcitabine in biliary tract and gallbladder carcinomas.
BMC Cancer. 10:6312010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Saito S, Ghosh M, Morita K, Hirano T, Miwa
M and Todoroki T: The genetic differences between gallbladder and
bile duct cancer cell lines. Oncol Rep. 16:949–956. 2006.PubMed/NCBI
|
|
9
|
Selaru FM, Olaru AV, Kan T, et al:
MicroRNA-21 is overexpressed in human cholangiocarcinoma and
regulates programmed cell death 4 and tissue inhibitor of
metalloproteinase 3. Hepatology. 49:1595–1601. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mott JL, Kobayashi S, Bronk SF and Gores
GJ: mir-29 regulates Mcl-1 protein expression and apoptosis.
Oncogene. 26:6133–6140. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Watanabe M, Chigusa M, Takahashi H,
Nakamura J, Tanaka H and Ohno T: High level of CA19-9, CA50, and
CEA-producible human cholangiocarcinoma cell line changes in the
secretion ratios in vitro or in vivo. In Vitro Cell Dev Biol Anim.
36:104–109. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Akiyoshi K, Kamada M, Akiyama N, et al:
Morphological study of cholangiocarcinoma cell line, TK with
three-dimensional cell culture. Mol Med Rep. 9:1359–1364.
2014.PubMed/NCBI
|
|
13
|
Manome Y, Wen PY, Dong Y, Tanaka T,
Mitchell BS, Kufe DW and Fine HA: Viral vector transduction of the
human deoxycytidine kinase cDNA sensitizes glioma cells to the
cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat
Med. 2:567–573. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kamada M, Ikeda K, Fujioka K, et al:
Expression of mRNAs of urocortin and corticotropin-releasing factor
receptors in malignant glioma cell lines. Anticancer Res.
32:5299–5307. 2012.PubMed/NCBI
|
|
15
|
Funamizu N, Lacy CR, Fujita K, Furukawa K,
Misawa T, Yanaga K and Manome Y: Tetrahydrouridine inhibits cell
proliferation through cell cycle regulation regardless of cytidine
deaminase expression levels. PLoS One. 7:e374242012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suzuki R, Kojima H, Moriyama H and Manome
Y: Utilization of caspase-14 promoter for selective transgene
expression in squamous layers of cholesteatoma in the middle ear. J
Intl Adv Otol. 8:21–29. 2012.
|
|
17
|
Manome Y, Wen PY, Chen L, et al: Gene
therapy for malignant gliomas using replication incompetent
retroviral and adenoviral vectors encoding the cytochrome P450 2B1
gene together with cyclophosphamide. Gene Ther. 3:513–520.
1996.
|
|
18
|
Funamizu N, Okamoto A, Kamata Y, et al: Is
the resistance of gemcitabine for pancreatic cancer settled only by
overexpression of deoxycytidine kinase? Oncol Rep. 23:471–475.
2010.PubMed/NCBI
|
|
19
|
de Marsh RW, Alonzo M, Bajaj S, et al:
Comprehensive review of the diagnosis and treatment of biliary
tract cancer 2012. Part I: diagnosis-clinical staging and
pathology. J Surg Oncol. 106:332–338. 2012.PubMed/NCBI
|
|
20
|
Yonemori K, Ueno H, Okusaka T, et al:
Severe drug toxicity associated with a single-nucleotide
polymorphism of the cytidine deaminase gene in a Japanese cancer
patient treated with gemcitabine plus cisplatin. Clin Cancer Res.
11:2620–2624. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakahira S, Nakamori S, Tsujie M, et al:
Involvement of ribonucleotide reductase M1 subunit overexpression
in gemcitabine resistance of human pancreatic cancer. Int J Cancer.
120:1355–1363. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ohhashi S, Ohuchida K, Mizumoto K, et al:
Down-regulation of deoxycytidine kinase enhances acquired
resistance to gemcitabine in pancreatic cancer. Anticancer Res.
28:2205–2212. 2008.PubMed/NCBI
|
|
23
|
Duxbury MS, Ito H, Zinner MJ, Ashley SW
and Whang EE: RNA interference targeting the M2 subunit of
ribonucleotide reductase enhances pancreatic adenocarcinoma
chemosensitivity to gemcitabine. Oncogene. 23:1539–1548. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kobayashi H, Murakami Y, Uemura K, Sudo T,
Hashimoto Y, Kondo N and Sueda T: Human equilibrative nucleoside
transporter 1 expression predicts survival of advanced
cholangiocarcinoma patients treated with gemcitabine-based adjuvant
chemotherapy after surgical resection. Ann Surg. 256:288–296. 2012.
View Article : Google Scholar
|
|
25
|
Murata A, Amano R, Yamada N, Kimura K,
Yashiro M, Nakata B and Hirakawa K: Prognostic predictive values of
gemcitabine sensitivity-related gene products for unresectable or
recurrent biliary tract cancer treated with gemcitabine alone.
World J Surg Oncol. 11:1172013. View Article : Google Scholar
|
|
26
|
Sebastiani V, Ricci F, Rubio-Viqueira B,
et al: Immuno-histochemical and genetic evaluation of deoxycytidine
kinase in pancreatic cancer: relationship to molecular mechanisms
of gemcitabine resistance and survival. Clin Cancer Res.
12:2492–2497. 2006. View Article : Google Scholar
|
|
27
|
Hapke D, Stegmann A and Mitchell B:
Retroviral transfer of deoxycytidine kinase into tumor cell lines
enhances nucleoside toxicity. Cancer Res. 56:2343–2347.
1996.PubMed/NCBI
|
|
28
|
Mori R, Ishikawa T, Ichikawa Y, et al:
Human equilibrative nucleoside transporter 1 is associated with the
chemosensitivity of gemcitabine in human pancreatic adenocarcinoma
and biliary tract carcinoma cells. Oncol Rep. 17:1201–1205.
2007.
|
